Hormone Therapy in 2026: What the Research Actually Says

For two decades, hormone therapy has carried a reputation shaped almost entirely by a single 2002 study — the Women's Health Initiative — whose early, incomplete headlines linked HRT to breast cancer and heart disease risk.

Subsequent re-analysis of that same data, along with two decades of additional research, told a more nuanced story: for most healthy women who start hormone therapy within 10 years of menopause onset or before age 60, the benefit-risk profile is favorable, and for many, meaningfully protective for bone density and cardiovascular health.

The Menopause Society's current position statement affirms hormone therapy as the most effective treatment available for vasomotor symptoms — hot flashes and night sweats — as well as genitourinary symptoms, when appropriately prescribed and monitored.

That 'appropriately prescribed and monitored' part matters. Dosing isn't one-size-fits-all, and it shouldn't be static. The right formulation and delivery method (patch, gel, pill) depends on personal and family history, and doses should be reassessed as labs and symptoms change — not set once and left alone for years.

This is also why hormone therapy shouldn't be treated as a stand-alone prescription. It works best paired with baseline and follow-up labs, a documented family history review, and a doctor who's actually tracking your response over time — not a one-time script.